The role of botulinum toxin type B (Myobloc) in the treatment of hyperkinetic facial lines.

@article{Kim2003TheRO,
  title={The role of botulinum toxin type B (Myobloc) in the treatment of hyperkinetic facial lines.},
  author={Eugene J Kim and Alexander L Ramirez and Jay B Reeck and Corey S. Maas},
  journal={Plastic and reconstructive surgery},
  year={2003},
  volume={112 5 Suppl},
  pages={88S-93S; discussion 94S-97S}
}
Botulinum toxin type B was studied for the management of hyperkinetic facial lines. It showed clinical longevity of up to 12 weeks on subjective rating scales and 8 weeks on objective rating scales. Botulinum toxin type B has shown relative safety but can have autonomic side effects at higher total doses, which limits the possibility of continued dose escalation. Although these findings may preclude its use as a primary modality for the use in hyperkinetic facial lines, botulinum toxin type B… CONTINUE READING